Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Navamedic ASA ( (DE:N1A) ) has provided an update.
Navamedic ASA has announced the launch of Flexilev[®] in OraFID[®], a novel dosing dispenser for Parkinson’s treatment, available in pharmacies by late December/early January. This product allows for precise, personalized dosing adjustments, enhancing treatment efficacy and minimizing side effects. Navamedic will manage the launch in Scandinavia, while Orion Corporation will handle marketing and distribution across 27 European countries, potentially strengthening Navamedic’s market position and expanding its reach.
More about Navamedic ASA
Navamedic ASA is a leading company in the pharmaceutical industry, committed to delivering innovative healthcare solutions to improve patient outcomes. With a strong presence in Scandinavia and partnerships across Europe, Navamedic continues to expand its portfolio and enhance its impact in the healthcare sector.
Average Trading Volume: 89,778
Current Market Cap: NOK518M
See more data about N1A stock on TipRanks’ Stock Analysis page.